Compare Amphastar Pharmaceuticals Inc (AMPH) vs Fidelity National Information Servcs Inc (FIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Fidelity National Information Servcs Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.9 (market cap $868.62M), while Fidelity National Information Servcs Inc trades at $41.67 (market cap $22.05B). The key difference: Fidelity National Information Servcs Inc is far larger — about 25.4× Amphastar Pharmaceuticals Inc's market cap, and Fidelity National Information Servcs Inc pays a 4.12% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | FIS | |
|---|---|---|
Market Cap | $868.62M | $22.05B |
Sector | Health | Technology |
52-Week High | $30.81 | $72.77 |
52-Week Low | $16.87 | $37.72 |
Enterprise Value | $1.27B | $42.56B |
Dividend Yield | — | 4.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $19.87, down 2.19% today, with a bullish technical signal from moving averages and ADX indicators. The company reported Q2 2026 EPS of $0.91, beating expectations, but missed in Q4 2025 and Q1 2026. Revenue for 2025 was $719.89M with a net income margin of 10.76%, while valuation ratios like P/E of 12.08 and EV/EBITDA of 6.57 suggest reasonable pricing. Recent news highlights growth from new product launches and ongoing FDA compliance efforts.
The outlook is mixed with growth opportunities from proprietary drugs and biosimilars, but risks include regulatory scrutiny and earnings volatility. Analyst sentiment is cautious with 25% buy ratings, reflecting concerns over execution and market pressures. Investors should weigh solid cash flow generation against competitive and regulatory headwinds for balanced exposure.
FIS trades at $41.64, down 2.05% today, with technical indicators showing bearish momentum despite attractive valuation metrics including a P/E of 6.57 and P/S of 1.82. The company reported Q2 2026 earnings of $1.48 per share, beating estimates, while lowering full-year guidance due to capital markets weakness. Recent developments include global expansion of Digital One Commercial platform and recognition as world's best treasury management software.
FIS presents a compelling value opportunity with strong banking solutions growth and improving cash flow, though near-term headwinds in capital markets create uncertainty. The stock trades at a discount to analyst consensus target of $50.18, with 58% of analysts maintaining buy ratings, suggesting potential upside if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →
